Streetbeat News

Equity Actions

ZETA

Zeta Global Holdings (NYSE:ZETA) has received mixed analyst ratings over the last three months, with a recent shift towards more bullish views. The average 12-month price target for ZETA has increased to $13.2, up from $12.50. Analysts from Morgan Stanley, Barclays, and Needham have updated their ratings and price targets, reflecting optimism based on ZETA's performance and market position. ZETA's financials show strong revenue growth and efficient cost management but highlight challenges in ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:00 pm

AMPE

Ampio Pharmaceuticals, Inc. (AMPE) has notified H.C. Wainwright & Co., LLC of its decision to terminate their At The Marketing Offering Agreement dated September 18, 2023. This agreement was for an at-the-market equity distribution program. The termination will be effective on March 6, 2024. Additionally, AMPE filed a post-effective amendment to withdraw and remove any unsold or unissued securities under its Registration Statement, including shares covered by the at-the-market offering agreement.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 8:51 pm

BROS

Dutch Bros Inc. announced the pricing of its secondary public offering of 8 million shares of Class A common stock at $29.05 per share, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 8:24 pm

SHC

Sotera Health's stock price is trading lower following the announcement of a secondary offering of 25 million shares by its selling stockholders.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 8:22 pm

APLS

In the past three months, 18 analysts have provided diverse ratings for Apellis Pharmaceuticals (NASDAQ:APLS), with a consensus 12-month price target of $75.94, marking a 12.6% increase from the previous target. The ratings range from bullish to bearish, reflecting varied perspectives on the company's performance and outlook. Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company, has shown significant revenue growth and strong profitability despite challenges in market capitalization, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 8:01 pm

GO

Analysts have diverse opinions on Grocery Outlet Holding (NASDAQ:GO), with recent evaluations showing a shift towards a more positive outlook. The average 12-month price target is now $30.2, down from $34.50. Analyst actions include adjustments to ratings and price targets, reflecting changes in market conditions and company performance. Grocery Outlet's financials indicate solid revenue growth, exceptional net margin, and strong ROE and ROA, with a debt-to-equity ratio below industry average.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 8:00 pm

VST

Vistra shares are trading higher following the announcement of its FY23 results and the authorization of an additional $1.5 billion to its share buyback program.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 7:57 pm

GSK

PPH

PTEU

A group of 11 European stocks, dubbed 'Granolas' by Goldman Sachs, has outperformed the global market with lower volatility and higher yields compared to 'The Magnificent Seven' tech stocks. These companies, operating in sectors like healthcare, pharmaceuticals, luxury goods, consumer staples, industrial manufacturing, and software technology, offer advantages such as lower valuation multiples, higher dividend yields, and less volatility. Notable companies include GSK, Roche, ASML, Nestle, Novo Nordisk, Novartis, L'Oreal, LVMH, AstraZeneca, Sanofi, and SAP. For investors interested in these stocks, ETFs like the VanEck Pharmaceutical ETF (PPH) and Pacer Trendpilot European Index ETF (PTEU) are recommended.

Portfolio Pulse from Stjepan Kalinic

February 28, 2024 | 7:43 pm

CJJD

China Jo-Jo Drugstores announced a 1-for-20 reverse stock split, leading to its shares trading lower.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 6:20 pm

APO

Apollo Global Management (APO) received an upgrade from JPMorgan analyst Kenneth Worthington, from Neutral to Overweight, with a price target of $122. The upgrade is based on Apollo's strong position in the alternative asset management space, particularly in private credit, and its innovative insurance strategy. The company's leadership is praised for its creativity, and its business model is highlighted for offering cheaper fee-related earnings through a creative third-party capital structure. Shares of Apollo Global Management rose by 0.99% to $111.92.

Portfolio Pulse from Priya Nigam

February 28, 2024 | 6:18 pm